Tags : Skyhawk

PharmaShots Weekly Snapshot (May 11-15, 2020)

1. Janssen to Present Updated Results of JNJ-4528 in P-Ib/II CARTITUDE-1 Study for Multiple Myeloma at ASCO 2020 Published: May 14, 2020 | Tags: Janssen, Update, Results, JNJ-4528, P-Ib/II, CARTITUDE-1, Study, Multiple Myeloma, ASCO 2. Samsung Bioepis Reports Results of Ontruzant (biosimilar, trastuzumab) in P-III Follow-up Study (SB3-G31-BC-E) for Early or Locally Advanced HER2-Positive Breast Cancer […]Read More

Celgene Signs an Exclusive Worldwide License Agreement with Skyhawk to

Shots: Skyhawk to receive $80M up front, milestones, and royalties on sales. Celgene to get exclusive WW option to license IPR for the number of Skyhawk’s candidates targeting multiple autoimmune disorder, oncology, and immuno-oncology targets. Post option exercising, Celgene will be responsible for further development and commercialization of products In 2018, the companies collaborated to […]Read More

Genentech Signs an Exclusive Option and License Agreement with Skyhawk

Shots: Skyhawk to receive up front, more than $2B as option fee & milestones, royalties on sales and will utilize its SkySTAR technology platform to discover and develop RNA splicing modifiers targeting oncology & neurological disorders Genentech to get an exclusive WW license to develop & commercialize RNA splicing modifiers targeting neurodegenerative diseases and cancer […]Read More